SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.04 EUR
+0.14 (+0.94%)
Taking everything into account, 1SXP scores 6 out of 10 in our fundamental rating. 1SXP was compared to 19 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
In the past year 1SXP had a positive cash flow from operations.
1SXP had positive earnings in each of the past 5 years.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
1SXP has a Return On Assets of 9.16%. This is amongst the best in the industry. 1SXP outperforms 89.47% of its industry peers.
With an excellent Return On Equity value of 16.42%, 1SXP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
1SXP has a Return On Invested Capital of 13.06%. This is amongst the best in the industry. 1SXP outperforms 89.47% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 9.26%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
With a decent Profit Margin value of 14.85%, 1SXP is doing good in the industry, outperforming 78.95% of the companies in the same industry.
1SXP's Profit Margin has improved in the last couple of years.
1SXP has a better Operating Margin (18.95%) than 73.68% of its industry peers.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
Looking at the Gross Margin, with a value of 33.71%, 1SXP is doing worse than 63.16% of the companies in the same industry.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for 1SXP remains at a similar level compared to 5 years ago.
The debt/assets ratio for 1SXP has been reduced compared to a year ago.
2.2 Solvency
1SXP has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as 1SXP would need 2.43 years to pay back of all of its debts.
1SXP's Debt to FCF ratio of 2.43 is amongst the best of the industry. 1SXP outperforms 89.47% of its industry peers.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a better Debt to Equity ratio (0.09) than 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.46
WACC8.92%
2.3 Liquidity
A Current Ratio of 1.50 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP's Current ratio of 1.50 is fine compared to the rest of the industry. 1SXP outperforms 68.42% of its industry peers.
A Quick Ratio of 1.12 indicates that 1SXP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.12, 1SXP is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
The Earnings Per Share has been growing by 13.78% on average over the past years. This is quite good.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 3.04% in the last year.
The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.92% yearly.
Based on estimates for the next years, 1SXP will show a quite strong growth in Revenue. The Revenue will grow by 8.05% on average per year.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y13.92%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y8.05%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.51, which indicates a correct valuation of 1SXP.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 89.47% of the companies listed in the same industry.
1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.84.
The Price/Forward Earnings ratio is 14.66, which indicates a correct valuation of 1SXP.
89.47% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.40. 1SXP is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.51 | ||
| Fwd PE | 14.66 |
4.2 Price Multiples
1SXP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1SXP is cheaper than 89.47% of the companies in the same industry.
68.42% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.42 | ||
| EV/EBITDA | 8.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.7
PEG (5Y)1.13
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.21%. Purely for dividend investing, there may be better candidates out there.
The stock price of 1SXP dropped by -30.21% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.60. 1SXP pays more dividend than 89.47% of the companies in the same industry.
1SXP's Dividend Yield is slightly below the S&P500 average, which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (12/29/2025, 5:29:50 PM)
15.04
+0.14 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.27B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts80
Price Target23.9 (58.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.21%
PT rev (3m)-20.06%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-12.33%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)-5.48%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.73%
Revenue NY rev (3m)-6.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.51 | ||
| Fwd PE | 14.66 | ||
| P/S | 2.3 | ||
| P/FCF | 64.42 | ||
| P/OCF | 12.59 | ||
| P/B | 2.54 | ||
| P/tB | 2.63 | ||
| EV/EBITDA | 8.58 |
EPS(TTM)0.97
EY6.45%
EPS(NY)1.03
Fwd EY6.82%
FCF(TTM)0.23
FCFY1.55%
OCF(TTM)1.19
OCFY7.94%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.7
PEG (5Y)1.13
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC8.92%
ROIC/WACC1.46
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y13.92%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y8.05%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y22.47%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 15.51 and the Price/Book (PB) ratio is 2.54.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 16.45%.